Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy

JAMA: The Journal of the American Medical Association

Volumn 266, Issue 12, 1991, Pages 1672-1677

  Steinherz, Laurel J ^a   Steinherz, Peter G ^a   Tan, Charlotte T C ^a   Heller, Glenn ^a   Murphy, M Lois ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT;

ADULT; ARTICLE; CANCER; CARDIOTOXICITY; ECHOCARDIOGRAPHY; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTHRACYCLINE; ARRHYTHMIA; CHILD; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HEART; HEART DISEASES; HUMAN; LINEAR MODELS; MYOCARDIAL CONTRACTION; NEOPLASMS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0025850827     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1991.03470120074036     Document Type: Article

References (23)

1. Tan CT, Tasaka H, Yu KP, Murphy L, Karnofsky D. Daunomycin an antitumor antibiotic in the treatment of neoplastic disease. Cancer. 1967;20:333-353.
2. Bristow MR, Billingham ME, Mason JW, Daniels J. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep. 1978;62:873-879.
3. Lefrak EA, Pitha J, Rosenheim S, Gottlieb J. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
4. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults: review of 100 cases. Am J Med. 1977;62:200-208.
5. Bristow MR. Pathophysiologic basis for cardiac monitoring in patients receiving anthracyclines. In: Crook ST, Reich SD, eds. Anthracyclines: Current Status and New Developments. New York, NY: Academic Press; 1980:255-271.
6. Von Hoff DD, Layard M, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
7. Dresdale A, Bonow R, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from post surgical adjuvant treatment of patients with soft tissue sarcomas. Cancer. 1983;52:51-60.
8. Steinherz L, Steinherz P, Tan C. Cardiac failure more than six years post anthracyclines. Med Pediatr Oncol. 1987;15:326.
9. Gilladoga AC, Manuel C, Tan CTC, Wollner N, Sternberg SS, Murphy ML. The cardiotoxicity of Adriamycin and daunomycin in children. Cancer. 1976;37:1070-1078.
10. Bloom K, Bini R, Williams C, Sonley M, Gribbin MA. Echocardiography in Adriamycin cardiotoxicity. Cancer. 1978;41:1265-1269.
11. Schwartz RG, Mckenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: a seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109-1118.
12. Singer JW, Narahara KA, Ritchie JL, Hamilton GW, Kennedy JW. Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy. Cancer Treat Rep. 1978;62:945-948.
13. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol. 1986;58:607-613.
14. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med. 1983;99:745-749.
15. Weiss AT, Manthel RW. Experience with the use of Adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to lack of cardiac toxicity. Cancer. 1977;40:2046-2052.
16. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-138.
17. Steinherz L, Murphy ML, Steinherz P, Rosen G, Robins J, Tan C. Cardiac function studies in children 4-11 years following cancer chemotherapy including anthracyclines. Proc Am Soc Clin Oncol. 1984;3:198.
18. Steinherz L, Murphy ML, Steinherz P, Robins J, Tan C. Long-term cardiac follow-up 4-13 years post anthracycline therapy. World Congr Pediatr Cardiol. 1985;2:58.
19. Steinherz L, Murphy ML, Steinherz P, Robins J, Tan C. Long-term cardiac follow-up 4-13 years post anthracycline therapy. In: Doyle E, Engle MA, Gersony W, Rashkin W, Talner N, eds. Pediatric Cardiology. New York, NY: Springer-Verlag; 1986:1056-1061.
20. Lipshultz S, Colan S, Sanders S, Sallan SE. Late cardiac effects of doxorubicin in childhood acute lymphoblastic leukemia (ALL). Blood. 1987;70:234a.
21. Lipshultz S, Colan S, Sanders S, Sallan SE. Late cardiac effects of doxorubicin in childhood lymphoblastic leukemia. J Am Coll Cardiol. 1988;11:135a.
22. Steinherz L, Steinherz P, Tan C, Murphy L. Cardiac toxicity 4-20 years after completing anthracycline therapy. Proc Am Soc Clin Oncol. 1989;8:296.
23. Lipshultz S, Colan S, Sanders S, Sallan SE. Cardiac mechanics after growth hormone therapy in pediatric Adriamycin recipients. Pediatr Res. 1989;25:153a.